The self-governing body has reached an agreement on the reimbursement of Clesrovimab and has added the new supplementary fee ZE191 to the 2026 DRG Catalog. With this move, the German hospital reimbursement system establishes the basis for a specific reimbursement option for the drug.
For manufacturers and investors, the decision emphasizes the importance of continuously monitoring the developments of DRGs, supplemental fees, and reimbursement rates.
Whether it involves new reimbursement pathways, reimbursement prospects, or Market Access strategies: We support companies in assessing regulatory changes early on and successfully integrating them into their market strategy.
Please feel free to contact us.
Author: Healthcare Heads GmbH
Phone: +49 431 800 1470
E-Mail: info@healthcareheads.com